Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation

被引：48

作者：

Jia, Hejin ^{[1
]}

Wang, Zhenguang ^{[1
]}

Wang, Yao ^{[1
]}

Liu, Yang ^{[2
]}

Dai, Hanren ^{[1
]}

Tong, Chuan ^{[1
]}

Guo, Yelei ^{[1
]}

Guo, Bo ^{[2
]}

Ti, Dongdong ^{[1
]}

Han, Xiao ^{[1
]}

Yang, Qingming ^{[1
]}

Wu, Zhiqiang ^{[1
]}

Han, Weidong ^{[1
]}

机构：

[1] Chinese Peoples Liberat Army Gen Hosp, Biotherapeut Dept, Mol & Immunol Dept, 28 Fuxing Rd, Beijing 100853, Peoples R China

[2] Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Hematol, 28 Fuxing Rd, Beijing 100853, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2019年 / 12卷 / 1期

基金：

中国国家自然科学基金;

关键词：

Chimeric antigen receptor; CAR-T; Bispecific CAR-T; GVHD; Haploidentical CAR-T; VERSUS-HOST-DISEASE; PHASE-I; GRAFT; INFUSION; LEUKEMIA; CHILDREN;

D O I：

10.1186/s13045-019-0741-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundChimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the potential of optimizing the durability of remission by this approach in patients with B cell acute lymphoblastic leukemia (B-ALL) remains a critical unanswered question so far.Case presentationWe treated an adult patient with relapsed and refractory B-ALL after haploidentical hematopoietic stem cell transplantation (HSCT) by administering haploidentical CAR-T cells targeting both CD19 and CD22 following preparative lymphodepleting chemotherapy. This patient has remained in minimal residual disease-negative remission for more than 14months and has been tapered off graft versus host disease prophylaxis.ConclusionsCAR simultaneously targeting CD19 and CD22 has the potential of inducing long-term remission in patients with B-ALL.

引用

页数：9

共 50 条

[1] Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
Hejin Jia
Zhenguang Wang
Yao Wang
Yang Liu
Hanren Dai
Chuan Tong
Yelei Guo
Bo Guo
Dongdong Ti
Xiao Han
Qingming Yang
Zhiqiang Wu
Weidong Han
Journal of Hematology & Oncology, 12
[2] MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell Transplantation
Zhang, Xin-Yue
Dai, Hai-Ping
Zhang, Ling
Liu, Si-Ning
Dai, Yin
Wu, De-Pei
Tang, Xiao-Wen
ONCOTARGETS AND THERAPY, 2021, 14 : 5197 - 5204
[3] First-Line Consolidation Therapy with CD19/CD22 Bispecific CAR-T Cells for MRD Positive B-ALL Maybe Feasible
Song, Xianmin
BLOOD, 2022, 140 : 12749 - 12749
[4] CD19 CAR-T Cell Therapy in Children with Relapsed and Refractory B-ALL
Molostova, Olga
Shelikhova, Larisa
Muzalevsky, Yakov
Kazachenok, Alexey
Khismatullina, Rimma
Abugova, Julia
Kurnikova, Elena
Trakhtman, Pavel
Pershin, Dmitry
Zubachenko, Viktoria
Fadeeva, Maria
Popov, Alexander M.
Illarionova, Olga
Miakova, Natalia
Litvinov, Dmitry
Novichkova, Galina
Maschan, Alexey
Maschan, Michael
BLOOD, 2021, 138
[5] Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Lihong An
Yuehui Lin
Biping Deng
Zhichao Yin
Defeng Zhao
Zhuojun Ling
Tong Wu
Yongqiang Zhao
Alex H. Chang
Chunrong Tong
Shuangyou Liu
BMC Cancer, 22
[6] Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Wenjie Li
Lixia Ding
Wenhua Shi
Xinyu Wan
Xiaomin Yang
Jing Yang
Tianyi Wang
Lili Song
Xiang Wang
Yani Ma
Chengjuan Luo
Jingyan Tang
Longjun Gu
Jing Chen
Jun Lu
Yanjing Tang
Benshang Li
Journal of Translational Medicine, 21
[7] Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Li, Wenjie
Ding, Lixia
Shi, Wenhua
Wan, Xinyu
Yang, Xiaomin
Yang, Jing
Wang, Tianyi
Song, Lili
Wang, Xiang
Ma, Yani
Luo, Chengjuan
Tang, Jingyan
Gu, Longjun
Chen, Jing
Lu, Jun
Tang, Yanjing
Li, Benshang
JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
[8] Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Dai, Hanren
Wu, Zhiqiang
Jia, Hejin
Tong, Chuan
Guo, Yelei
Ti, Dongdong
Han, Xiao
Liu, Yang
Zhang, Wenying
Wang, Chunmeng
Zhang, Yajing
Chen, Meixia
Yang, Qingming
Wang, Yao
Han, Weidong
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
[9] CD19 CAR-T Cells Treatment Conferred a Sustained Remission in Patients with Chemotherapy-Refractory MRD in B-ALL
Lu, Wenyi
Wei, Yunxiong
Cao, Yaqing
Xiao, Xia
Li, Qing
Lyu, Hairong
Jiang, Yili
Zhang, Huan
Wang, Jia
Li, Xin
Jiang, Yanyu
Meng Juanxia
Ting, Yuan
Zhu, Haibo
He, Xiaoyuan
Jin, Xin
Sun, Rui
Sui, Tao
Liu, Kaiqi
Zhao, Mingfeng
BLOOD, 2020, 136
[10] Production and characterization of haploidentical CD19 CAR T cells: Validated to induce a continuous complete remission in a patient with relapsed refractory B-cell ALL
Prasongtanakij, Somsak
Anurathapan, Usanarat
Vanichapol, Thitinee
Jittorntrum, Bunyada
Atjanasuppat, Korakot
Pongpitcha, Pongpak
Pakakasama, Samart
Songdej, Duantida
Sirachainan, Nongnuch
Paisooksantivatana, Karan
Borwaornpinyo, Suparerk
Andersson, Borje S.
Hongeng, Suradej
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (01) : 44 - 51

← 1 2 3 4 5 →